-
1
-
-
0037138446
-
Incidence and mortality from stomach cancer in Japan, Slovenia and the USA
-
Lambert R, Guilloux A, Oshima A, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002; 97: 811-18.
-
(2002)
Int J Cancer
, vol.97
, pp. 811-818
-
-
Lambert, R.1
Guilloux, A.2
Oshima, A.3
-
2
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
-
4
-
-
84863343266
-
Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010
-
Jing JJ, Liu HY, Hao JK, et al. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol 2012; 18: 1262-9.
-
(2012)
World J Gastroenterol
, vol.18
, pp. 1262-1269
-
-
Jing, J.J.1
Liu, H.Y.2
Hao, J.K.3
-
5
-
-
71349083374
-
Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: A population-level analysis of trends and projections
-
Yeh JM, Goldie SJ, Kuntz KM, et al. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control 2009; 20: 2021-9.
-
(2009)
Cancer Causes Control
, vol.20
, pp. 2021-2029
-
-
Yeh, J.M.1
Goldie, S.J.2
Kuntz, K.M.3
-
6
-
-
33745547767
-
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
-
Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2903-2909
-
-
Wagner, A.D.1
Grothe, W.2
Haerting, J.3
-
8
-
-
34447255242
-
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
-
Lutz MP, Wilke H, Wagener DJ, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25: 2580-5.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2580-2585
-
-
Lutz, M.P.1
Wilke, H.2
Wagener, D.J.3
-
9
-
-
34848927813
-
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Results of a phase II trial
-
Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007; 18: 1673-9.
-
(2007)
Ann Oncol
, vol.18
, pp. 1673-1679
-
-
Lorenzen, S.1
Hentrich, M.2
Haberl, C.3
-
10
-
-
84858283338
-
The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: A single-institution experience
-
Ben Aharon I, Purim O, Kundel Y, et al. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience. Anticancer Drugs 2012; 23: 313-20.
-
(2012)
Anticancer Drugs
, vol.23
, pp. 313-320
-
-
Ben Aharon, I.1
Purim, O.2
Kundel, Y.3
-
11
-
-
84859966845
-
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403)
-
Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 2012; 32: 1403-8.
-
(2012)
Anticancer Res
, vol.32
, pp. 1403-1408
-
-
Tamura, S.1
Imano, M.2
Takiuchi, H.3
-
12
-
-
84861540507
-
Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: Aretrospective analysis of single institution
-
Inal A, Kaplan MA, Kucukoner M, et al. Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: aretrospective analysis of single institution. Neoplasma 2012; 59: 233-6.
-
(2012)
Neoplasma
, vol.59
, pp. 233-236
-
-
Inal, A.1
Kaplan, M.A.2
Kucukoner, M.3
-
13
-
-
34548258255
-
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group
-
Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25: 3205-9.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3205-3209
-
-
Ajani, J.A.1
Moiseyenko, V.M.2
Tjulandin, S.3
-
14
-
-
0024420685
-
Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
-
Hsiang YH, Lihou MG, Liu LF,. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
-
(1989)
Cancer Res
, vol.49
, pp. 5077-5082
-
-
Hsiang, Y.H.1
Lihou, M.G.2
Liu, L.F.3
-
15
-
-
0028225471
-
Comparison of topoisomerase i inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
-
Tanizawa A, Fujimori A, Fujimori Y, et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836-42.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 836-842
-
-
Tanizawa, A.1
Fujimori, A.2
Fujimori, Y.3
-
16
-
-
0028276113
-
CPT-11 Gastrointestinal Cancer Study Group
-
Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer
-
Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033-8.
-
(1994)
Gan to Kagaku Ryoho
, vol.21
, pp. 1033-1038
-
-
Futatsuki, K.1
Wakui, A.2
Nakao, I.3
-
17
-
-
0141887353
-
Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial
-
Kohne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89: 997-1001.
-
(2003)
Br J Cancer
, vol.89
, pp. 997-1001
-
-
Kohne, C.H.1
Catane, R.2
Klein, B.3
-
18
-
-
30844449923
-
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
-
Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005; 50: 2218-23.
-
(2005)
Dig Dis Sci
, vol.50
, pp. 2218-2223
-
-
Enzinger, P.C.1
Kulke, M.H.2
Clark, J.W.3
-
19
-
-
22344456355
-
Irinotecan plus cisplatin combination against metastatic gastric cancer: Phase II study
-
Altinbas M, Er O, Ozkan M, et al. Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study. Med Oncol 2005; 22: 153-60.
-
(2005)
Med Oncol
, vol.22
, pp. 153-160
-
-
Altinbas, M.1
Er, O.2
Ozkan, M.3
-
20
-
-
0032919992
-
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
-
Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-23.
-
(1999)
J Clin Oncol
, vol.17
, pp. 319-323
-
-
Boku, N.1
Ohtsu, A.2
Shimada, Y.3
-
21
-
-
78650620190
-
Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials
-
Wang DL, Gu DY, Huang HY, et al. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials. World J Gastroenterol 2010; 16: 5889-94.
-
(2010)
World J Gastroenterol
, vol.16
, pp. 5889-5894
-
-
Wang, D.L.1
Gu, D.Y.2
Huang, H.Y.3
-
22
-
-
71249128928
-
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study
-
Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet 2009; 10: 1063-9.
-
(2009)
Lancet
, vol.10
, pp. 1063-1069
-
-
Boku, N.1
Yamamoto, S.2
Fukuda, H.3
-
23
-
-
79958270201
-
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
-
Komatsu Y, Takahashi Y, Kimura Y, et al. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anticancer Drugs 2011; 22: 576-83.
-
(2011)
Anticancer Drugs
, vol.22
, pp. 576-583
-
-
Komatsu, Y.1
Takahashi, Y.2
Kimura, Y.3
-
24
-
-
79953025190
-
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
-
Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011; 14: 72-80.
-
(2011)
Gastric Cancer
, vol.14
, pp. 72-80
-
-
Narahara, H.1
Iishi, H.2
Imamura, H.3
-
25
-
-
0242356584
-
Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC)
-
.: Abstract
-
Hawkins R, Cunningham D, Soerbye H, et al. Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 2003; 22: Abstract 1032.
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 1032
-
-
Hawkins, R.1
Cunningham, D.2
Soerbye, H.3
-
26
-
-
84871096142
-
FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study
-
.: Abstract
-
Glenjen N, Hammerling K, Hatlevoll L, et al. FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: a randomized phase II study. J Clin Oncol 2012; 30: Abstract 71.
-
(2012)
J Clin Oncol
, vol.30
, pp. 71
-
-
Glenjen, N.1
Hammerling, K.2
Hatlevoll, L.3
-
27
-
-
84864350608
-
Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report
-
.: Abstract
-
Kishimoto T, Imamura H, Uedou F, et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): final report. J Clin Oncol 2010; 28: Abstract 4015.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4015
-
-
Kishimoto, T.1
Imamura, H.2
Uedou, F.3
-
28
-
-
77953464230
-
A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer
-
.: Abstract
-
Boukovinas I, Androulakis N, Polyzos A, et al. A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer. J Clin Oncol 2009; 27: Abstract 4536.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4536
-
-
Boukovinas, I.1
Androulakis, N.2
Polyzos, A.3
-
29
-
-
0032558314
-
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
-
Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
-
(1998)
Lancet
, vol.352
, pp. 609-613
-
-
Moher, D.1
Pham, B.2
Jones, A.3
-
30
-
-
0032583387
-
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
-
Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
-
(1998)
Stat Med
, vol.17
, pp. 2815-2834
-
-
Parmar, M.K.1
Torri, V.2
Stewart, L.3
-
31
-
-
12744274510
-
Heterogeneity testing in meta-analysis of genome searches
-
Zintzaras E, Ioannidis JP,. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-37.
-
(2005)
Genet Epidemiol
, vol.28
, pp. 123-137
-
-
Zintzaras, E.1
Ioannidis, J.P.2
-
32
-
-
0021909115
-
β-Blockade during and after myocardial infarction: An overview of the randomized trials
-
Yusuf S, Peto R, Lewis J, et al. β-Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
-
(1985)
Prog Cardiovasc Dis
, vol.27
, pp. 335-371
-
-
Yusuf, S.1
Peto, R.2
Lewis, J.3
-
33
-
-
0028659004
-
Operating characteristics of a rank correlation test for publication bias
-
Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
-
(1994)
Biometrics
, vol.50
, pp. 1088-1101
-
-
Begg, C.B.1
Mazumdar, M.2
-
34
-
-
0032430986
-
Power and sample size calculations for studies involving linear regression
-
Dupont WD, Plummer WD, Jr,. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19: 589-601.
-
(1998)
Control Clin Trials
, vol.19
, pp. 589-601
-
-
Dupont, W.D.1
Plummer, Jr.W.D.2
-
35
-
-
48849094297
-
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
-
Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-7.
-
(2008)
Ann Oncol
, vol.19
, pp. 1450-1457
-
-
Dank, M.1
Zaluski, J.2
Barone, C.3
-
36
-
-
77949326012
-
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
-
Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010; 21: 71-7.
-
(2010)
Ann Oncol
, vol.21
, pp. 71-77
-
-
Moehler, M.1
Kanzler, S.2
Geissler, M.3
-
37
-
-
13244266683
-
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803
-
Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-28.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4319-4328
-
-
Bouche, O.1
Raoul, J.L.2
Bonnetain, F.3
-
38
-
-
22144469838
-
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
-
Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-8.
-
(2005)
Br J Cancer
, vol.92
, pp. 2122-2128
-
-
Moehler, M.1
Eimermacher, A.2
Siebler, J.3
-
39
-
-
57249084776
-
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution
-
Nakashima K, Hironaka S, Boku N, et al. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution. Jpn J Clin Oncol 2008; 38: 810-15.
-
(2008)
Jpn J Clin Oncol
, vol.38
, pp. 810-815
-
-
Nakashima, K.1
Hironaka, S.2
Boku, N.3
-
40
-
-
79959631111
-
Residual embryonic cells as precursors of a Barrett's-like metaplasia
-
Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011; 145: 1023-35.
-
(2011)
Cell
, vol.145
, pp. 1023-1035
-
-
Wang, X.1
Ouyang, H.2
Yamamoto, Y.3
-
41
-
-
84865123975
-
Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer
-
Reim D, Gertler R, Novotny A, et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012; 19: 2108-18.
-
(2012)
Ann Surg Oncol
, vol.19
, pp. 2108-2118
-
-
Reim, D.1
Gertler, R.2
Novotny, A.3
-
42
-
-
77950860026
-
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram
-
Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010; 251: 640-6.
-
(2010)
Ann Surg
, vol.251
, pp. 640-646
-
-
Strong, V.E.1
Song, K.Y.2
Park, C.H.3
|